The treatment regimen developed from this dose-finding study has now been carried forward into the DIABIL-2 clinical trial to assess the efficacy and safety of ultra-low doses of recombinant human IL-2 (rhIL-2) in children and adults with T1D [37]. The gene discussed is IL2; the disease is type 1 diabetes mellitus.